Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Necdin, encoded by the **NDN** gene, is a member of the melanoma antigen (MAGE) protein family, located in the Prader-Willi syndrome (PWS) chromosomal region 15q11–q13, and expressed exclusively from the paternal allele due to genomic imprinting[1][2][4][5]. Necdin is primarily expressed in postmitotic neurons and regulates neuronal differentiation, promotes cell survival, and suppresses both cellular proliferation and apoptosis[1][2][3][4][6]. It functions as a transcription factor, binding specific DNA sequences and modulating transcriptional activity, and interacts with regulatory proteins such as E2F1, p53, neurotrophin receptors, and others, integrating complex networks governing neuronal vitality[3][4]. Loss of necdin expression is implicated in Prader-Willi syndrome and neurodevelopmental abnormalities, with reduced expression also associated with increased proliferation and metastasis in various cancers, indicating a tumor suppressor role[2][3][4]. No currently approved drugs target necdin directly, and there are no established safety issues or direct pharmacological interventions related to this protein.
Not applicable, as no direct drug targeting reported
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Necdin, MAGE family member (NDN).